<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01491477</url>
  </required_header>
  <id_info>
    <org_study_id>P01-04</org_study_id>
    <nct_id>NCT01491477</nct_id>
  </id_info>
  <brief_title>INFUSE ® Bone Graft/CORNERSTONE-SR® Allograft Ring/ATLANTIS® Anterior Cervical Plate System Pivotal Trial</brief_title>
  <official_title>Study of Recombinant Human Bone Morphogenetic Protein-2 and Absorbable Collagen Sponge With the Cornerstone-SR™ Allograft Ring and the ATLANTIS™ Anterior Cervical Plate System in Treatment of Patients With Degenerative Cervical Disc Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Spinal and Biologics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Spinal and Biologics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the implant (INFUSE™ BONE GRAFT/CORNERSTONE-SR™&#xD;
      Allograft Ring/ATLANTIS™ Anterior Cervical Plate system) as a method of facilitating spinal&#xD;
      fusion in patients with cervical symptomatic degenerative disc disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">April 2005</completion_date>
  <primary_completion_date type="Actual">April 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Success</measure>
    <time_frame>12 month</time_frame>
    <description>A patient will be considered an overall success if all of the following conditions are met:&#xD;
fusion;&#xD;
pain/disability (Neck Disability Index) Improvement;&#xD;
maintenance or improvement in neurological status;&#xD;
no serious adverse event classified as &quot;implant associated&quot; or &quot;implant/surgical procedure associated&quot;;&#xD;
no additional surgical procedure classified as a &quot;failure&quot;.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disc Height Measurement</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Health Status (SF-36)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Status (neck pain, arm pain)</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Perceived Effect</measure>
    <time_frame>12 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Degenerative Cervical Disc Disease</condition>
  <arm_group>
    <arm_group_label>INFUSE™ Bone Graft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Autogenous bone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™</intervention_name>
    <description>Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.</description>
    <arm_group_label>INFUSE™ Bone Graft</arm_group_label>
    <other_name>Recombinant human bone morphogenetic protein-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™</intervention_name>
    <description>Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.</description>
    <arm_group_label>Autogenous bone</arm_group_label>
    <other_name>Autograft</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cervical disc disease defined as: intractable radiculopathy and/or myelopathy with at&#xD;
             least one of the following items producing symptomatic nerve root and/or spinal cord&#xD;
             compression which is documented by diagnostic imaging procedures:&#xD;
&#xD;
               -  herniated disc;&#xD;
&#xD;
               -  osteophyte formation;&#xD;
&#xD;
               -  decreased disc height;&#xD;
&#xD;
               -  thickening of ligamentous tissue;&#xD;
&#xD;
               -  disc degeneration; and/or&#xD;
&#xD;
               -  facet joint degeneration.&#xD;
&#xD;
          2. Has preoperative Neck Disability Index score &gt; 30;&#xD;
&#xD;
          3. Has single cervical disc disease level requiring fusion from C2 to C7;&#xD;
&#xD;
          4. No previous surgical intervention at the involved fusion level;&#xD;
&#xD;
          5. Unresponsive to nonoperative treatment for approximately six weeks or has the presence&#xD;
             of progressive symptoms or signs of nerve root or spinal cord compression in face of&#xD;
             continued nonoperative management;&#xD;
&#xD;
          6. Is at least 18 years of age, inclusive at time of surgery;&#xD;
&#xD;
          7. If of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use&#xD;
             adequate contraception for 1 year following surgery;&#xD;
&#xD;
          8. Is willing and able to comply with study plan and sign the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has cervical spinal condition requiring surgical treatment other than symptomatic&#xD;
             cervical disc disease at the involved level.&#xD;
&#xD;
          2. Has a condition which requires postoperative medications that interfere with fusion,&#xD;
             such as steroids or prolonged non-steroidal anti-inflammatory drugs excluding routine&#xD;
             perioperative anti-inflammatory drugs. This does not include low dose aspirin for&#xD;
             prophylactic anticoagulation.&#xD;
&#xD;
          3. Has been previously diagnosed with osteopenia, or osteomalacia.&#xD;
&#xD;
          4. Has any of the following that may be associated with a diagnosis of osteoporosis (if&#xD;
             &quot;Yes&quot; to any of the below risk factors, a DEXA Scan will be required to determine&#xD;
             eligibility).&#xD;
&#xD;
               1. Postmenopausal Non-Black female over 60 years of age and weighs less than 140&#xD;
                  pounds.&#xD;
&#xD;
               2. Postmenopausal female that has sustained a non-traumatic hip, spine, or wrist&#xD;
                  fracture.&#xD;
&#xD;
               3. Male over the age of 70.&#xD;
&#xD;
               4. Male over the age of 60 that has sustained a non-traumatic hip or spine fracture.&#xD;
&#xD;
             If the level of BMD is a T score of -3.5 or a T score of -2.5 with vertebral crush&#xD;
             fracture, the patient is excluded from the study.&#xD;
&#xD;
          5. Has presence of active malignancy or prior history of malignancy, except for basal&#xD;
             cell carcinoma of the skin.&#xD;
&#xD;
          6. Has overt or active bacterial infection, either local or systemic.&#xD;
&#xD;
          7. Has a documented titanium alloy allergy or intolerance.&#xD;
&#xD;
          8. Is mentally incompetent. If questionable, obtain psychiatric consult.&#xD;
&#xD;
          9. Is a prisoner.&#xD;
&#xD;
         10. Is an alcohol and/or drug abuser as defined by currently undergoing treatment for&#xD;
             alcohol and/or drug usage.&#xD;
&#xD;
         11. Has received drugs which may interfere with bone metabolism within two weeks prior to&#xD;
             the planned date of spinal fusion surgery (e.g., steroids or methotrexate), excluding&#xD;
             routine perioperative anti-inflammatory drugs.&#xD;
&#xD;
         12. Has a history of autoimmune disease (Systemic Lupus Erythematosus or Dermatomyositis).&#xD;
&#xD;
         13. Has a history of exposure to injectable collagen implants.&#xD;
&#xD;
         14. Has a history of hypersensitivity to protein pharmaceuticals (monoclonal antibodies or&#xD;
             gamma globulins) or collagen.&#xD;
&#xD;
         15. Has received treatment with an investigational therapy within 28 days prior to&#xD;
             implantation surgery or such treatment is planned during the 16 weeks following&#xD;
             rhBMP-2/ACS implantation.&#xD;
&#xD;
         16. Has received any previous exposure to any/all BMP's of either human or animal&#xD;
             extraction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2011</verification_date>
  <study_first_submitted>December 12, 2011</study_first_submitted>
  <study_first_submitted_qc>December 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2011</study_first_posted>
  <last_update_submitted>August 1, 2013</last_update_submitted>
  <last_update_submitted_qc>August 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
    <mesh_term>Intervertebral Disc Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

